JP2021073194A5 - - Google Patents

Download PDF

Info

Publication number
JP2021073194A5
JP2021073194A5 JP2020218615A JP2020218615A JP2021073194A5 JP 2021073194 A5 JP2021073194 A5 JP 2021073194A5 JP 2020218615 A JP2020218615 A JP 2020218615A JP 2020218615 A JP2020218615 A JP 2020218615A JP 2021073194 A5 JP2021073194 A5 JP 2021073194A5
Authority
JP
Japan
Prior art keywords
salt
composition
composition according
weight
hetre
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020218615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021073194A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021073194A publication Critical patent/JP2021073194A/ja
Publication of JP2021073194A5 publication Critical patent/JP2021073194A5/ja
Pending legal-status Critical Current

Links

JP2020218615A 2013-11-15 2020-12-28 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩 Pending JP2021073194A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904600P 2013-11-15 2013-11-15
US61/904,600 2013-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019212877A Division JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Publications (2)

Publication Number Publication Date
JP2021073194A JP2021073194A (ja) 2021-05-13
JP2021073194A5 true JP2021073194A5 (enExample) 2021-11-25

Family

ID=52669635

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016530882A Pending JP2016538288A (ja) 2013-11-15 2014-11-17 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2019212877A Expired - Fee Related JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2020218615A Pending JP2021073194A (ja) 2013-11-15 2020-12-28 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016530882A Pending JP2016538288A (ja) 2013-11-15 2014-11-17 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
JP2019212877A Expired - Fee Related JP6818851B2 (ja) 2013-11-15 2019-11-26 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩

Country Status (6)

Country Link
US (3) US10017453B2 (enExample)
EP (3) EP3068757B1 (enExample)
JP (3) JP2016538288A (enExample)
CN (2) CN105899485B (enExample)
ES (1) ES2727387T3 (enExample)
WO (1) WO2015071766A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
EP4364572A3 (en) * 2017-03-14 2024-07-10 Ibiden Co., Ltd. Plant activator
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2022090482A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
FR3148365A1 (fr) * 2023-05-04 2024-11-08 Pierre Fabre Dermo-Cosmetique Oxylipines dans le traitement de la séborrhée et/ou de l’acné

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3055923A (en) * 1960-03-25 1962-09-25 Baxter Laboratories Inc Fatty acid salts
IE47777B1 (en) 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
JPH04507397A (ja) 1988-01-14 1992-12-24 フリッツ，アンデルス 湿疹治療用薬剤製造における必須脂肪酸の使用法
GB9111900D0 (en) 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH05186342A (ja) 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
JP2000500879A (ja) * 1996-09-20 2000-01-25 アセロジエニクス・インコーポレイテツド 炎症性疾患の診断及びメディエータ
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
CA2332272A1 (en) * 1998-05-15 1999-11-25 University Of Vermont Novel analogs of 16-hydroxyeicosatetraenoic acid
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
TR200201250T2 (tr) * 1999-11-09 2002-09-23 Alcon, Inc Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
WO2004072013A1 (ja) * 2003-02-14 2004-08-26 Taisho Pharmaceutical Co.,Ltd. ヒドロキシエイコサジエン酸化合物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
EP1852114B1 (en) 2005-02-14 2019-09-18 Suntory Holdings Limited Composition containing dihomo-y-linolenic acid (dgla) as active ingredient
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
JP5101894B2 (ja) 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
GB0907601D0 (en) 2009-05-01 2009-06-10 Equateq Ltd Novel methods
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
MX2014004710A (es) 2011-10-19 2014-12-10 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX2016008953A (es) 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
WO2015185698A1 (en) 2014-06-04 2015-12-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113230244A (zh) 2015-12-18 2021-08-10 艾菲穆恩有限公司 包含15-hepe的组合物及其使用方法
US20170196825A1 (en) 2016-01-07 2017-07-13 Dignity Sciences Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2021073194A5 (enExample)
JP2019081783A5 (enExample)
JP2689991B2 (ja) 組成物
JP5558113B2 (ja) 生理冷却剤を含む組成物
EP3322488B1 (en) Cosmetic composition
JP2024057010A5 (enExample)
JP2017526738A5 (enExample)
JP2019189650A5 (enExample)
JP2008543854A (ja) 炎症状態を治療するための組成物および方法
JP6682872B2 (ja) 口腔用シリカ分散安定化剤およびこれを含有する歯磨剤組成物
JP2015531344A5 (enExample)
WO2007102243A1 (ja) 外用の医薬組成物
JP2011503167A5 (enExample)
JP2016532654A5 (enExample)
JP2009544665A5 (enExample)
JP2014515383A5 (enExample)
JP2015504860A5 (enExample)
JP2003342131A (ja) 頭皮治療剤組成物
JP2023041793A5 (enExample)
JP2011529936A5 (enExample)
HRP20161594T1 (hr) Pripravci za liječenje rozaceje koji sadrže kitozan i amid dikarboksilne kiseline
RU2006137282A (ru) Химически устойчивые композиции 4-гидрокси-тамоксифена
JP6598744B2 (ja) 歯磨き剤組成物
HRP20230641T1 (hr) Pripravak za topikalnu uporabu na bazi karnozin-magnezij kompleksa
JPWO2023286780A5 (enExample)